CD8A and melanoma: In mice C57Bl6 challenged with melanoma cells MB16-F10, the vaccine candidate using VSSP as adjuvant induced a cytotoxic T cell response with anti-tumoral activity, which could be mediated by CD8+ T lymphocytes.